Danish Drugmaker Leo Pharma Is Said to Seek Bank Pitches for IPO

Danish pharmaceutical company Leo Pharma A/S is preparing for a potential initial public offering (IPO), marking a strategic shift for the 115-year-old family-owned drugmaker. The company has invited investment banks to compete for underwriting roles, signaling active preparations for a public listing, according to insiders familiar with the process. The move follows growing trends of legacy European firms seeking public capital to accelerate expansion, particularly in competitive sectors like dermatology and biotech. No official timeline or valuation has been disclosed, but the IPO could reshape Leo Pharma’s ownership structure after over a century under private control. Analysts speculate the listing may attract significant investor interest given the company’s strong portfolio in chronic skin disease treatments and global market presence.